Loading institutional data...
Loading institutional data...
Held by 228 of 5,944 reporting institutions (92th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $24.69 today, the market must believe free cash flow compounds -4.9%/yr for a decade (off $152M normalized FCF).
The market's -4.9% is more conservative than its 7-yr track record.
2-stage DCF · 0.04B shares · net debt $214M
mean 30.6% · volatility σ 50% · implied rate exceeded in 5/7 yrs
Central path = implied -4.9%/yr growth; shaded band = ±1σ (50%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $148M buybacks = $148M returned on $137M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 1%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~4.7% on $372M of debt.
Cash of $159M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-18
Where each multiple sits in its own 14-yr range · 20th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 25.7 | 25.3 | 27.3 | 25.9 | 29.9 | 27.4 | 24.3 | 20.6 |
| R&D | 16.5 | 17.1 | 13.8 | 10.3 | 12.7 | 11.3 | 11.6 | 16.1 |
| SG&A | 52.6 | 47.7 | 45.0 | 36.8 | 38.2 | 39.9 | 42.0 | 50.8 |
| Operating Income | 4.7 | 2.5 | 10.8 | 16.6 | 9.0 | 13.0 | -10.5 | 2.6 |
| Income Tax | 0.0 | 0.1 | -29.2 | 2.7 | -0.4 | 2.9 | 5.2 | 1.4 |
| Net Income | -0.1 | -2.6 | 33.9 | 7.8 | 2.4 | 6.2 | -14.2 | 1.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PCRX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M 100.0% | $701.0M 100.0% | $675.0M 100.0% | $666.8M 100.0% | $541.5M 100.0% | $429.6M 100.0% | $421.0M 100.0% | $337.3M 100.0% | $286.6M 100.0% | $276.4M 100.0% |
| Cost of Revenue | $149.7M 20.6% | $170.4M 24.3% | $184.7M 27.4% | $199.3M 29.9% | $140.3M 25.9% | $117.3M 27.3% | $106.7M 25.3% | $86.8M 25.7% | $87.9M 30.7% | $110.1M 39.8% |
| Research & Development | $117.3M 16.1% | $81.6M 11.6% | $76.3M 11.3% | $84.8M 12.7% | $55.5M 10.3% | $59.4M 13.8% | $72.1M 17.1% | $55.7M 16.5% | $57.3M 20.0% | $45.7M 16.5% |
| Selling, General & Admin | $368.8M 50.8% | $294.1M 42.0% | $269.4M 39.9% | $254.5M 38.2% | $199.3M 36.8% | $193.5M 45.0% | $200.8M 47.7% | $177.3M 52.6% | $161.5M 56.3% | $152.6M 55.2% |
| Total Operating Expenses | $707.2M 97.4% | $774.3M 110.5% | $587.3M 87.0% | $606.8M 91.0% | $451.6M 83.4% | $383.3M 89.2% | $410.5M 97.5% | $321.4M 95.3% | $311.6M 108.7% | $308.4M 111.6% |
| Operating Income | $19.2M 2.6% | -$73.4M -10.5% | $87.7M 13.0% | $60.0M 9.0% | $89.9M 16.6% | $46.4M 10.8% | $10.5M 2.5% | $15.9M 4.7% | -$24.9M -8.7% | -$32.0M -11.6% |
| Interest Expense | $17.4M 2.4% | $16.6M 2.4% | $20.3M 3.0% | $40.0M 6.0% | $31.8M 5.9% | $25.7M 6.0% | $23.6M 5.6% | $21.9M 6.5% | $18.0M 6.3% | $7.1M 2.6% |
| Interest & Investment Income | $22.7M 3.1% | $19.7M 2.8% | $11.4M 1.7% | $4.5M 0.7% | $896K 0.2% | $4.6M 1.1% | $7.4M 1.8% | $6.5M 1.9% | $4.1M 1.4% | $1.3M 0.5% |
| Other Income (Expense), net | -$2.3M -0.3% | $10.3M 1.5% | -$26.0M -3.8% | -$46.7M -7.0% | -$33.5M -6.2% | -$26.3M -6.1% | -$21.2M -5.0% | -$16.3M -4.8% | -$17.5M -6.1% | -$5.8M -2.1% |
| Pretax Income | $16.9M 2.3% | -$63.1M -9.0% | $61.7M 9.1% | $13.3M 2.0% | $56.4M 10.4% | $20.1M 4.7% | -$10.7M -2.6% | -$425K -0.1% | -$42.5M -14.8% | -$37.8M -13.7% |
| Income Tax Expense | $9.8M 1.4% | $36.5M 5.2% | $19.7M 2.9% | -$2.6M -0.4% | $14.4M 2.7% | -$125.4M -29.2% | $268K 0.1% | $46K 0.0% | $140K 0.0% | $105K 0.0% |
| Net Income | $7.0M 1.0% | -$99.6M -14.2% | $42.0M 6.2% | $15.9M 2.4% | $42.0M 7.8% | $145.5M 33.9% | -$11.0M -2.6% | -$471K -0.1% | -$42.6M -14.9% | -$37.9M -13.7% |
| Per Share | ||||||||||
| EPS (Basic) | $0.16 | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| EPS (Diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| Weighted Avg Shares (Basic) | 44.6M | 46.2M | 46.2M | 45.5M | 44.3M | 42.7M | 41.5M | 40.9M | 39.8M | 37.2M |
| Weighted Avg Shares (Diluted) | 45.0M | 46.2M | 52.0M | 46.5M | 45.6M | 43.7M | 41.5M | 40.9M | 39.8M | 37.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PCRX | $1.0B | 154.3× | 11.2× | 1.4× | 3.6% | 79.4% | 1.0% | 1.0% | 0.7% | 3.4× | 228 |
Peers = companies sharing PCRX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position